PATENT CLAIM ANALYSIS

Application Number: 16198143
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-04
Patent Classification: ["424", "472000"]

Abstract:
Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.

Claim (Index 1):
A sustained release oral solid dosage form comprising a therapeutically effective amount of nalbuphine or a pharmaceutically acceptable salt thereof in a sustained release delivery system, wherein the dosage form provides a mean Tmax at about 1.77 (\u00b11.539) to about 8.01 (\u00b12.196) hours after oral administration to human subjects and maintains a plateau of a relatively constant blood serum level of nalbuphine which does not consistently increase or decrease from time point to time point.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 98.0
- Lexical Diversity: 1.85185
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12154496', '13773136', '15658234', '14290413', '14319833']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7830250817162941
- 35 USC 102 Novelty (BERT): 0.5684555196002671
- Combined Prediction Score: 0.7615681255046914
- Mean Citation Score: 425.958024
- Max Citation Score: 459.1525
- Similarity Product: 398.98234806165095

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test